Journal
Therapeutic Advances in Neurological Disorders
Publication Date
1-1-2021
Volume
14
First Page
1756286421993999
Document Type
Open Access Publication
DOI
10.1177/1756286421993999
Rights and Permissions
Wundes A, Wray S, Gold R, Singer BA, Jasinska E, Ziemssen T, de Seze J, Repovic P, Chen H, Hanna J, Messer J, Miller C, Naismith RT. Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. Ther Adv Neurol Disord. 2021 Mar 19;14:1756286421993999. doi: 10.1177/1756286421993999. © The Author(s), 2021. Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Recommended Citation
Wundes, Annette; Wray, Sibyl; Gold, Ralf; Singer, Barry A; Jasinska, Elzbieta; Ziemssen, Tjalf; de Seze, Jerome; Repovic, Pavle; Chen, Hailu; Hanna, Jerome; Messer, Jordan; Miller, Catherine; and Naismith, Robert T, "Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: Results from the randomized, double-blind, phase III EVOLVE-MS-2 study." Therapeutic Advances in Neurological Disorders. 14, 1756286421993999 (2021).
https://digitalcommons.wustl.edu/oa_4/163